title: Drug development of intranasally delivered peptides.
abstract: Intranasal drug delivery has attracted increasing attention as a noninvasive route of administration for therapeutic proteins and peptides. The delivery of therapeutic peptides through the nasal route provides an alternative to intravenous or subcutaneous injections. This review highlights the drug-development considerations unique to nasal therapeutics and discusses some of the factors and strategies that affect and can improve nasal absorption of peptides. The selectivity and good safety profile typical of peptide therapeutics, along with the dose limitation for intranasal administration, can provide challenges in drug development. Therefore, nasal peptide therapeutics often require special considerations in the nonclinical safety evaluations, such as determining drug exposure in the context of the maximum feasible dose in order to adequately prepare nasal products for clinical studies.
authors: Allon Therapeutics Inc., 1168 Hamilton St, Vancouver, British Columbia, V6B 2S2, Canada.
authors: Catherine
authors: C
authors: Campbell
authors: Bruce H
authors: BH
authors: Morimoto
authors: Daniela
authors: D
authors: Nenciu
authors: Anthony W
authors: AW
authors: Fox
mesh_terms: D000042:Absorption; D000281:Administration, Intranasal; D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism; D002626:Chemistry, Pharmaceutical; D004339:Drug Compounding; D015195:Drug Design; D006801:Humans; D009297:Nasal Mucosa / Q000378:metabolism*; D010455:Peptides / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity; D010539:Permeability; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D010455:Peptides